Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel, Pierre
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. [electronic resource] - European journal of cancer (Oxford, England : 1990) Jan 2016 - 181-7 p. digital
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
1879-0852
10.1016/j.ejca.2015.10.072 doi
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Non-Small-Cell Lung--mortality
Chemoradiotherapy--adverse effects
Cisplatin--therapeutic use
Consolidation Chemotherapy--adverse effects
Disease-Free Survival
Female
Humans
Induction Chemotherapy--adverse effects
Lung Neoplasms--mortality
Male
Middle Aged
Neoplasm Staging
Paclitaxel--therapeutic use
Radiotherapy Dosage
Risk Factors
Survival Analysis
Time Factors
Treatment Outcome
Vinblastine--analogs & derivatives
Vinorelbine
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. [electronic resource] - European journal of cancer (Oxford, England : 1990) Jan 2016 - 181-7 p. digital
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
1879-0852
10.1016/j.ejca.2015.10.072 doi
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Non-Small-Cell Lung--mortality
Chemoradiotherapy--adverse effects
Cisplatin--therapeutic use
Consolidation Chemotherapy--adverse effects
Disease-Free Survival
Female
Humans
Induction Chemotherapy--adverse effects
Lung Neoplasms--mortality
Male
Middle Aged
Neoplasm Staging
Paclitaxel--therapeutic use
Radiotherapy Dosage
Risk Factors
Survival Analysis
Time Factors
Treatment Outcome
Vinblastine--analogs & derivatives
Vinorelbine